Background: Portal vein thrombosis (PVT) is a rare but severe vascular disorder with an acute and a chronic course. Most patients have underlying liver cirrhosis; furthermore, thrombophilia is an important risk factor. However, idiopathic forms are also known. Methods: This review discusses nonsurgical treatment options in PVT. Results and Conclusion: Therapy of acute PVT is based on anticoagulation with heparin that is switched to oral anticoagulants, if applicable. Catheter-guided invasive therapy should be considered; however, patients with liver cirrhosis should be screened for portal hypertension before anticoagulation is mandatory. Therapy of chronic PVT is discussed controversially; therefore, a strict patient selection and an individual therapeutic decision are warranted depending on the etiology of PVT. Special forms of PVT including septic and malignant thrombosis as well as PVT in patients waiting for liver transplantation require particular therapy algorithms.

Keywords:
Acute portal vein thrombosis, Chronic portal vein thrombosis, Portal hypertension, Anticoagulation
1.
Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, Morard I, Lasser L, Langlet P, Denninger MH, Vidaud D, Condat B, Hadengue A, Primignani M, Garcia-Pagan JC, Janssen HL, Valla D: Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010;51:210-218.
2.
Davies M, Satyadas T, Akle CA: Spontaneous resolution of a superior mesenteric vein thrombosis after laparoscopic Nissen fundoplication. Ann R Coll Surg Engl 2002;84:177-180.
3.
DeLeve LD, Valla DC, Garcia-Tsao G: Vascular disorders of the liver. Hepatology 2009;49:1729-1764.
4.
Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D: Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000;32:466-470.
5.
Nonami T, Yokoyama I, Iwatsuki S, Starzl TE: The incidence of portal vein thrombosis at liver transplantation. Hepatology 1992;16:1195-1198.
6.
Delgado MG, Seijo S, Yepes I, Achecar L, Catalina MV, Garcia-Criado A, Abraldes JG, de la Pena J, Banares R, Albillos A, Bosch J, Garcia-Pagan JC: Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012;10:776-783.
7.
Senzolo M, Sartori MT, Rossetto V, Burra P, Cillo U, Boccagni P, Gasparini D, Miotto D, Simioni P, Tsochatzis E, Burroughs AK: Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012;32:919-927.
8.
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR; American College of Chest Physicians: Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e419S-494S.
9.
Arjal R, Trotter JF: International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure. Clin Liver Dis 2009;13:67-71.
10.
Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, Romano L, Balzano A: Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010;44:448-451.
11.
Senzolo M, Ferronato C, Burra P, Sartori MT: Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered. Intern Emerg Med 2009;4:161-162; author reply 163-164.
12.
Malkowski P, Pawlak J, Michalowicz B, Szczerban J, Wroblewski T, Leowska E, Krawczyk M: Thrombolytic treatment of portal thrombosis. Hepatogastroenterology 2003;50:2098-2100.
13.
Hollingshead M, Burke CT, Mauro MA, Weeks SM, Dixon RG, Jaques PF: Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 2005;16:651-661.
14.
Grisham A, Lohr J, Guenther JM, Engel AM: Deciphering mesenteric venous thrombosis: imaging and treatment. Vasc Endovascular Surg 2005;39:473-479.
15.
Kawanaka H, Akahoshi T, Kinjo N, Konishi K, Yoshida D, Anegawa G, Yamaguchi S, Uehara H, Hashimoto N, Tsutsumi N, Tomikawa M, Maehara Y: Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. Ann Surg 2010;251:76-83.
16.
Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, Hadengue A, Erlinger S, Valla D: Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001;120:490-497.
17.
Aguas M, Bastida G, Nos P, Beltran B, Grueso JL, Grueso J: Septic thrombophlebitis of the superior mesenteric vein and multiple liver abscesses in a patient with Crohn's disease at onset. BMC Gastroenterol 2007;7:22.
18.
Plemmons RM, Dooley DP, Longfield RN: Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect Dis 1995;21:1114-1120.
19.
Singh P, Yadav N, Visvalingam V, Indaram A, Bank S: Pylephlebitis - diagnosis and management. Am J Gastroenterol 2001;96:1312-1313.
20.
Baril N, Wren S, Radin R, Ralls P, Stain S: The role of anticoagulation in pylephlebitis. Am J Surg 1996;172:449-452; discussion 452-443.
21.
Tublin ME, Dodd GD 3rd, Baron RL: Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol 1997;168:719-723.
22.
Rossi S, Rosa L, Ravetta V, Cascina A, Quaretti P, Azzaretti A, Scagnelli P, Tinelli C, Dionigi P, Calliada F: Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. AJR Am J Roentgenol 2006;186:763-773.
23.
Vibert E, Azoulay D, Cunha AS, Adam R, Samuel D, Castaing D: Portal stenting for hepatocellular carcinoma extending into the portal vein in cirrhotic patients. J Surg Oncol 2013;107:696-701.
24.
Rodriguez-Castro KI, Porte RJ, Nadal E, Germani G, Burra P, Senzolo M: Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. Transplantation 2012;94:1145-1153.
25.
Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, Sauvanet A, Valla D, Durand F: Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005;54:691-697.
26.
Lendoire J, Raffin G, Cejas N, Duek F, Barros Schelotto P, Trigo P, Quarin C, Garay V, Imventarza O: Liver transplantation in adult patients with portal vein thrombosis: risk factors, management and outcome. HPB (Oxford) 2007;9:352-356.
27.
Selvaggi G, Weppler D, Nishida S, Moon J, Levi D, Kato T, Tzakis AG: Ten-year experience in porto-caval hemitransposition for liver transplantation in the presence of portal vein thrombosis. Am J Transplant 2007;7:454-460.
28.
Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, Harrison ME, Rakela J, Aqel BA: Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci 2013;58:1776-1780.
© 2015 S. Karger GmbH, Freiburg
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.